GLOBUS MEDICAL INC - A (GMED) Stock Fundamental Analysis
USA - NYSE:GMED - US3795772082 - Common Stock
57.92 USD
+0.08 (+0.14%)
Taking everything into account, GMED scores 6 out of 10 in our fundamental rating. GMED was compared to 191 industry peers in the Health Care Equipment & Supplies industry. GMED gets an excellent profitability rating and is at the same time showing great financial health properties. GMED has a decent growth rate and is not valued too expensively. These ratings would make GMED suitable for quality investing!
1. Profitability
1.1 Basic Checks
GMED had positive earnings in the past year.
In the past year GMED had a positive cash flow from operations.
GMED had positive earnings in each of the past 5 years.
GMED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.19%, GMED belongs to the top of the industry, outperforming 89.01% of the companies in the same industry.
With an excellent Return On Equity value of 8.30%, GMED belongs to the best of the industry, outperforming 82.20% of the companies in the same industry.
With an excellent Return On Invested Capital value of 9.00%, GMED belongs to the best of the industry, outperforming 88.48% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GMED is in line with the industry average of 8.46%.
The last Return On Invested Capital (9.00%) for GMED is above the 3 year average (7.50%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.19% | ||
| ROE | 8.3% | ||
| ROIC | 9% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)7.5%
ROIC(5y)7.39%
1.3 Margins
GMED has a Profit Margin of 13.58%. This is amongst the best in the industry. GMED outperforms 90.58% of its industry peers.
In the last couple of years the Profit Margin of GMED has declined.
With an excellent Operating Margin value of 19.48%, GMED belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
In the last couple of years the Operating Margin of GMED has declined.
The Gross Margin of GMED (68.97%) is better than 76.44% of its industry peers.
In the last couple of years the Gross Margin of GMED has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.48% | ||
| PM (TTM) | 13.58% | ||
| GM | 68.97% |
OM growth 3Y-4.88%
OM growth 5Y-4.91%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-3.49%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), GMED is creating some value.
The number of shares outstanding for GMED has been increased compared to 1 year ago.
The number of shares outstanding for GMED has been increased compared to 5 years ago.
GMED has a worse debt/assets ratio than last year.
2.2 Solvency
GMED has an Altman-Z score of 8.57. This indicates that GMED is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 8.57, GMED belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
The Debt to FCF ratio of GMED is 0.00, which is an excellent value as it means it would take GMED, only 0.00 years of fcf income to pay off all of its debts.
GMED has a Debt to FCF ratio of 0.00. This is amongst the best in the industry. GMED outperforms 95.29% of its industry peers.
GMED has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
GMED has a Debt to Equity ratio of 0.00. This is in the better half of the industry: GMED outperforms 74.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.57 |
ROIC/WACC1.07
WACC8.44%
2.3 Liquidity
GMED has a Current Ratio of 4.07. This indicates that GMED is financially healthy and has no problem in meeting its short term obligations.
GMED has a Current ratio of 4.07. This is in the better half of the industry: GMED outperforms 69.11% of its industry peers.
GMED has a Quick Ratio of 2.26. This indicates that GMED is financially healthy and has no problem in meeting its short term obligations.
GMED has a Quick ratio of 2.26. This is comparable to the rest of the industry: GMED outperforms 58.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.07 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
GMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.59%, which is quite impressive.
GMED shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.19% yearly.
The Revenue has grown by 17.44% in the past year. This is quite good.
Measured over the past years, GMED shows a very strong growth in Revenue. The Revenue has been growing by 26.25% on average per year.
EPS 1Y (TTM)21.59%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%14.67%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%18.37%
3.2 Future
The Earnings Per Share is expected to grow by 12.10% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.25% on average over the next years.
EPS Next Y4.19%
EPS Next 2Y9.07%
EPS Next 3Y10.4%
EPS Next 5Y12.1%
Revenue Next Year13.98%
Revenue Next 2Y10.9%
Revenue Next 3Y9.46%
Revenue Next 5Y7.25%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 18.04, GMED is valued on the expensive side.
80.63% of the companies in the same industry are more expensive than GMED, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.20. GMED is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 15.51 indicates a correct valuation of GMED.
82.20% of the companies in the same industry are more expensive than GMED, based on the Price/Forward Earnings ratio.
GMED is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.71, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.04 | ||
| Fwd PE | 15.51 |
4.2 Price Multiples
GMED's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMED is cheaper than 91.10% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, GMED is valued cheaper than 92.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.97 | ||
| EV/EBITDA | 9.68 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GMED does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of GMED may justify a higher PE ratio.
PEG (NY)4.31
PEG (5Y)1.37
EPS Next 2Y9.07%
EPS Next 3Y10.4%
5. Dividend
5.1 Amount
No dividends for GMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:GMED (9/17/2025, 9:43:51 AM)
57.92
+0.08 (+0.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners100.4%
Inst Owner Change2.64%
Ins Owners0.69%
Ins Owner Change0%
Market Cap7.82B
Analysts76.19
Price Target84.2 (45.37%)
Short Float %5.17%
Short Ratio4.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.6%
Min EPS beat(2)-10.39%
Max EPS beat(2)11.6%
EPS beat(4)3
Avg EPS beat(4)9.28%
Min EPS beat(4)-10.39%
Max EPS beat(4)25.45%
EPS beat(8)5
Avg EPS beat(8)8.04%
EPS beat(12)8
Avg EPS beat(12)5.67%
EPS beat(16)11
Avg EPS beat(16)4.32%
Revenue beat(2)0
Avg Revenue beat(2)-3.9%
Min Revenue beat(2)-6.31%
Max Revenue beat(2)-1.49%
Revenue beat(4)2
Avg Revenue beat(4)-1.52%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)1.57%
Revenue beat(8)4
Avg Revenue beat(8)-2.13%
Revenue beat(12)6
Avg Revenue beat(12)-1.07%
Revenue beat(16)7
Avg Revenue beat(16)-1.09%
PT rev (1m)-0.55%
PT rev (3m)-3.92%
EPS NQ rev (1m)-1.06%
EPS NQ rev (3m)-2.69%
EPS NY rev (1m)1.36%
EPS NY rev (3m)-1.87%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-0.09%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.04 | ||
| Fwd PE | 15.51 | ||
| P/S | 2.98 | ||
| P/FCF | 14.97 | ||
| P/OCF | 11.69 | ||
| P/B | 1.82 | ||
| P/tB | 3.79 | ||
| EV/EBITDA | 9.68 |
EPS(TTM)3.21
EY5.54%
EPS(NY)3.74
Fwd EY6.45%
FCF(TTM)3.87
FCFY6.68%
OCF(TTM)4.95
OCFY8.55%
SpS19.45
BVpS31.81
TBVpS15.28
PEG (NY)4.31
PEG (5Y)1.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.19% | ||
| ROE | 8.3% | ||
| ROCE | 11.28% | ||
| ROIC | 9% | ||
| ROICexc | 9.48% | ||
| ROICexgc | 19.67% | ||
| OM | 19.48% | ||
| PM (TTM) | 13.58% | ||
| GM | 68.97% | ||
| FCFM | 19.89% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)7.5%
ROIC(5y)7.39%
ROICexc(3y)9.36%
ROICexc(5y)9.51%
ROICexgc(3y)18.38%
ROICexgc(5y)15.86%
ROCE(3y)9.4%
ROCE(5y)9.26%
ROICexcg growth 3Y25.82%
ROICexcg growth 5Y11.96%
ROICexc growth 3Y-3.93%
ROICexc growth 5Y-4.62%
OM growth 3Y-4.88%
OM growth 5Y-4.91%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-3.49%
GM growth 5Y-2.63%
F-Score9
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 53.97% | ||
| Cap/Sales | 5.59% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.4% | ||
| Profit Quality | 146.48% | ||
| Current Ratio | 4.07 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 8.57 |
F-Score9
WACC8.44%
ROIC/WACC1.07
Cap/Depr(3y)69.29%
Cap/Depr(5y)78.11%
Cap/Sales(3y)5.6%
Cap/Sales(5y)6.16%
Profit Quality(3y)194.29%
Profit Quality(5y)172.4%
High Growth Momentum
Growth
EPS 1Y (TTM)21.59%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%14.67%
EPS Next Y4.19%
EPS Next 2Y9.07%
EPS Next 3Y10.4%
EPS Next 5Y12.1%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%18.37%
Revenue Next Year13.98%
Revenue Next 2Y10.9%
Revenue Next 3Y9.46%
Revenue Next 5Y7.25%
EBIT growth 1Y203.64%
EBIT growth 3Y31.28%
EBIT growth 5Y20.06%
EBIT Next Year57.98%
EBIT Next 3Y25.83%
EBIT Next 5Y19.9%
FCF growth 1Y331.76%
FCF growth 3Y22.69%
FCF growth 5Y31.98%
OCF growth 1Y261.32%
OCF growth 3Y23.51%
OCF growth 5Y24.8%